We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Lorus Therapeutics has announced the discovery that IL-17E, a novel component
of the immune system, participates in the mechanism of Virulizin-mediated anticancer
activity, further elucidating the mechanism of action of this drug, which is
in a fully enrolled pivotal Phase III clinical trial for the treatment of pancreatic
cancer.
Progenics Pharmaceuticals has announced positive top-line results from a pivotal
Phase III clinical trial of its investigational drug, methylnaltrexone (MNTX)
for the treatment of opioid-induced constipation in patients with advanced medical
illness (AMI).
The FDA has approved a new indication for Bristol-Myers Squibb's and Otsuka
Pharmaceutical's schizophrenia drug Abilify, clearing it for treatment of Bipolar
I Disorder patients with a recent manic or mixed episode who had been stabilized
and then maintained for at least six weeks.
Curis has announced that the recent online issue of the Journal of the American
Society of Nephrology contains a preclinical report demonstrating that treatment
with BMP-7, a signaling protein that was discovered by scientists from Curis,
results in amelioration of two major complications of chronic kidney disease.
New long-term data suggest that, when initial monotherapy treatment with once-daily
Agilect tablets is started early in the course of Parkinson's disease (PD),
positive effects on functional impairments at one year can be maintained up
to 6.5 years.
DeCODE genetics has begun enrolling subjects in a Phase I clinical trial for
DG041, the company's developmental compound for the treatment of atherosclerosis
of the extremities, commonly known as peripheral arterial occlusive disease
(PAOD).
Renovis, a biopharmaceutical company focused on the discovery and development
of drugs to treat neurological diseases and disorders, has announced results
of its Phase II clinical trial studying REN-1654 in patients with post-herpetic
neuralgia.
Bayer Pharmaceuticals and Onyx Pharmaceuticals have announced the initiation
of a randomized, double-blind, placebo-controlled Phase III clinical trial of
BAY 43-9006 administered as a single agent in patients with advanced hepatocellular
carcinoma, or liver cancer.